BioCentury | Apr 10, 2018
Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest a SLIT3 fragment could help treat bone loss in osteoporosis. The fragment consists of the 130-mer, second leucine-rich repeat domain (LRDD2) of human SLIT3. In a mouse model of osteoporosis,...
BioCentury | Aug 8, 2016
Clinical News

RI-002 regulatory update

...a BLA from ADMA for R1-002, an IV immunoglobulin (IVIG), to treat primary immunodeficiency disease (PIDD...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...with Parkinson's disease (PD) Submit NDA 2H16 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 Primary immunodeficiency disease (PIDD...
...& Johnson (NYSE:JNJ) Sirukumab RA Submit global regulatory apps 3Q16 Green Cross Corp. (KSE:006280) IVIG-SN PIDD...
BioCentury | May 23, 2016
Financial News

ADMA completes debt financing

...million based upon FDA approval of a BLA for RI-002 to treat primary immunodeficiency disease (PIDD...
BioCentury | Jan 11, 2016
Finance

Sowing season

...PDUFA date 5/1/16 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 polyclonal intravenous immunoglobulin (IVIG) Primary immunodeficiency disease (PIDD...
BioCentury | Sep 28, 2015
Clinical News

Subgam-VF: Phase III started

...target: NA Description: 16% IgG product made from human plasma Indication: Treat primary immunodeficiency disease (PIDD...
BioCentury | Jun 29, 2015
Financial News

ADMA completes debt financing

...company plans to submit a BLA this year for RI-002 to treat primary immunodeficiency disease (PIDD...
BioCentury | Apr 6, 2015
Finance

Q is for quiet

...IBS-D) PDUFA date 2Q15 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 (intravenous immune globulin) Primary immunodeficiency disease (PIDD...
BioCentury | Mar 2, 2015
Clinical News

RI-002: Additional Phase III data

...Additional data from the open-label, U.S. Phase III ADMA-003 trial in 59 patients with PIDD who...
...standardized high levels of antibodies against respiratory syncytial virus (RSV) Indication: Treat primary immunodeficiency disease (PIDD...
BioCentury | Dec 22, 2014
Clinical News

RI-002: Phase III data

...Top-line data from the open-label, U.S. Phase III ADMA-003 trial in 59 patients with PIDD showed...
...standardized high levels of antibodies against respiratory syncytial virus (RSV) Indication: Treat primary immunodeficiency disease (PIDD...
Items per page:
1 - 10 of 15